CASE REPORTA 34-year-old woman, gravida 3 para 0, was referred to our institute at 37 weeks' gestation for evaluation of a fetal abdominal cystic mass. She had conceived by intrauterine insemination with ovulation induction after three spontaneous miscarriages. Because of her history, low-dose aspirin (81 mg/day) was administered in the current pregnancy up to 36 weeks' gestation. A routine fetal ultrasound examination in the second trimester showed no abnormal findings, but at 35 weeks of gestation a cystic mass was detected in the fetal abdomen. Detailed ultrasonography at referral revealed a retrovesical septate hypoechogenic mass measuring 77 × 76 × 73 mm within the fetal abdomen (Figure 1). Bilateral mild hydronephrosis was present, but there was no ascites. Cardiac anatomy and the extremities were normal. It was not possible to visualize the fetal external genitalia by ultrasound due to the late gestation and the sonographic findings were inconclusive. Magnetic resonance imaging (MRI) was then used to perform a detailed evaluation of the fetal abdominal mass. MRI confirmed that the abdominal mass was located in the midline posterior to the bladder and showed that it was connected to the dilated uterine cavity (Figure 2a). The mass was fluid-filled with a mid-plane septum (Figure 2b). A four-chamber appearance consisting of the septate mass and two small uterine cavities was observed (Figure 2c). These findings were consistent with a diagnosis of hydrometrocolpos with septate vagina and uterus didelphys. The rectum was not clearly visible in the T1-weighted image in which the presence of meconium appeared as hyperintense signals (Figure 2d). Although the cystic lesion was large and occupied the fetal abdomen, pulmonary hypoplasia was not observed on MRI.At 38 weeks' gestation a Cesarean section was performed due to the arrest of labor during induction with oxytocin. A female infant weighing 2438 g and with a length of 44 cm, and Apgar scores of 8 and 8 after 1 and 5 min, respectively, was delivered. Physical examination revealed abdominal distension, ambiguous genitalia and anal atresia. However, the face, limbs and digits were normal. There was a single perineal opening through which a urethral catheter was introduced, but
BACKGROUND To avoid hemolytic disease of the fetus and newborn resulting from maternal alloantibodies against fetal Rh antigens, anti-D immunoglobulin is routinely administered to RhD-negative pregnant women in Japan. Fetal RHD genotyping using cell-free DNA may prevent unnecessary antibody administration; however, current PCR-based methods, which detect RHD deletion, do not address the higher rates of RHD-positive D antigen-negative alleles in nonwhite populations without additional inspections. METHODS We developed an amplicon-sequencing method that could estimate the type of paternally inherited fetal RHD allele from 4 major RHD alleles in the Japanese population: the D antigen-positive allele (RHD*01, 92.9%) and 3 D antigen-negative alleles (RHD*01N.01, 6.6%; RHD*01EL.01, 0.3%; RHD*01N.04, 0.1%) using cell-free DNA obtained from the blood plasma of pregnant women. RESULTS The method correctly determined the fetal RhD type even when RhD-negative pregnant women possessed an RHD-positive D antigen-negative allele: RHD*01EL.01 or RHD*01N.04. CONCLUSIONS This method is a reliable noninvasive fetal RHD genotyping method for Japanese and other East Asian populations. The genotyping principle of amplifying 2 different regions using the same primer pair and distinguishing them by their sequence difference during the subsequent mapping procedure is also theoretically applicable to RHD-positive D antigen-negative alleles prevalent in Africans. Therefore, this method offers an opportunity to consider targeted administration of anti-D immunoglobulin to RhD-negative pregnant women in East Asian and African countries and to increase the specificity of the fetal RHD genotyping implemented nationwide in several European countries.
The expected live-birth rate with FP indicated that one in three oncofertility patients would not expect to have a live birth following oocyte retrieval and embryo cryopreservation. While the decision trees were useful as decision-making tools for women contemplating FP, in the context of the current restrictions on oocyte donation and the extremely small number of adoptions in Japan, the remaining options for fertility after cancer are limited. In order for cancer survivors to feel secure in their decisions, the decision tree may need to be adapted simultaneously with improvements to the social environment, such as greater support for adoption.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.